ALUNBRIG (brigatinib)
TherapyTakeda
ALUNBRIG (brigatinib) from Takeda is a kinase inhibitor used in biomarker-defined lung cancer populations.
Approvals
2
Indications
1
Biomarkers
1
Mapped tests
2
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and ALUNBRIG. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where ALUNBRIG is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Non-Small Cell Lung Cancer (NSCLC) Solid Tumor · Lung | ALK
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for ALUNBRIG.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering ALUNBRIG for eligible patients.
Test
FoundationOne CDx
Foundation Medicine, Inc.
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
Vysis ALK Break Apart FISH Probe Kit
Abbott Molecular, Inc.
Method
FISH
Specimen
Tissue (FFPE)
1 approvalView test profile →